Rapt Therapeutics Inc.
13F holders, Q3 2025 (September 30)3holders +1
1new positions
0sold out
$25.79avg. 13F price*
At the end of Q3 2025, 3 institutions reported holding Rapt Therapeutics Inc. in their 13F filings, up 1 from Q2 2025. 1 opened new positions and 0 sold out. The largest holders were Medicxi Ventures Management (Jersey) Ltd ($72.1M), Column Group LLC ($4.3M) and AJU IB Investment Co., Ltd. ($321K).
- Company
- Rapt Therapeutics Inc.
- CUSIP
- 75382E109
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $72.1M |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 2,794,000 shares bought and 1,162,538 shares sold, net +1,631,462 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Medicxi Ventures Management (Jersey) Ltd | 9.68% | New | 2,794,000 | $72.1M |
| Column Group LLC | 5.29% | Reduce -87.5% | 166,075 | $4.3M |
| AJU IB Investment Co., Ltd. | 0.28% | No change | 12,437 | $321K |
"% of holder's portfolio" is RAPT THERAPEUTICS INC's weight in each manager's 13F, not the share of Rapt Therapeutics Inc. the manager owns.